Dsuvia
Head of opioid advisory panel criticises FDA for complacency in ongoing crisis
January 28, 2019Medical Communications, Sales and Marketing Dsuvia, FDA, opioid crisis, opioids, pharma
The opioid crisis continues to be a top healthcare concern in the US, but the head of the FDA’s Anesthetic …
FDA controversially approves potent opioid up to ten times stronger than fentanyl
November 6, 2018Sales and Marketing Dsuvia, FDA, US, fentanyl, opioid crisis, opioids, pharma
Despite voices of criticism, the FDA has opted to approve AcelRX’s Dsuvia (sufentanil), an opioid medication said to be five …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
